Past Issue
Vol. 5, No. 3
MayJune
|
|
Past Issues
|
|
|
|
|
|
|
|
|
Letters
First Case of Human Ehrlichiosis in Mexico
To the Editor: Ehrlichiosis is a zoonotic disease transmitted to humans through the
bite of infected ticks (1). The first recognized human
ehrlichial infection, Sennetsu fever, was described in Japan in 1954 (2). The first case of human ehrlichiosis in the United States was
recognized in 1986 and was reported in 1987 (3). The disease is
caused by intracellular gram-negative bacteria of the Ehrlichia genus. The bacteria
can be found in the monocytes and granulocytes of peripheral blood. Human monocytic
ehrlichiosis is caused by E. chafeensis, and human granulocytic ehrlichiosis is
caused by E. equi or E. phagocytophilia, which was first recognized in 1994
(4). Most cases occur between April and September, and the
reservoirs are field animals such as rodents, deer, and dogs. The clinical spectrum of the
disease is similar to that of other febrile illnesses; without adequate and timely
treatment, approximately 5% of the patients die (5).
In the United States, more than 400 cases of serologically confirmed E. chaffensis
infection have been documented since 1996 (6). No cases have
been reported in Mexico.
In February 1997, we evaluated a 41-year-old male patient from Merida. The patient had
been exposed to ticks during activity in a rural area 1 week before the onset of illness.
Clinical manifestations included frequent hyperthermia, rash, myalgia, headache, anorexia,
fatigue, and cough. Physical examination showed bilateral cervical lymphadenopathy, and a
chest radiograph showed an interstitial bilateral infiltrate. Hematic cytometry showed
thrombocytopenia of 134 x 103/µL and 3200 leukocytes (1440 neutrophils/µL).
Hepatic transaminases were elevated, with an aspartate aminotransferase: 92 U/L (normal:
22 U/L), alanine aminotransferase: 48 U/L (normal: 18 U/L), gamma-glutamyltranspeptidase:
278 U/L (normal: 28 U/L); and globulins: 4.8 g/dL with a polyclonal pattern. No antibodies
against rickettsia, dengue virus, B-19 parvovirus, or HIV were detected. A serum sample
gave a positive reaction by indirect immunofluorescence assay against E. chaffeensis
at titers of 1:64 on week 2 and 1:128 on week 3. No infected monocytes or granulocytes
were observed in peripheral blood. Remission of the clinical manifestations began on week
4 and was completed on week 6.
This case indicates the existence of human ehrlichiosis in Yucatan, Mexico. Reactivity
to E. chaffeensis suggests human monocytic ehrlichiosis; however, as antibody
testing was not performed with E. phagocytophila or E. equi, the possibility
of human granulocytic ehrlichiosis cannot be excluded. In any event, case reports indicate
the need for deliberate search for cases. Dengue is endemic in this area of Mexico, and
ehrlichiosis should be considered as a differential diagnosis.
Renán A. Gongóra-Biachi,* Jorge Zavala-Velázquez, Carlos José
Castro-Sansores,* and Pedro González-Martínez*
*Centro de Investigaciones Regionales "Dr. Hideyo Noguchi,"
Mérida, Yucatán, México; and Facultad de Medicina, Universidad Autónoma de
Yucatán, Mérida, Yucatán, México
References
- Dumler SJ, Bakken JS.
Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis
1995;20:1102-10.
- Schaffner W, Standaert SM. Ehrlichiosisin
pursuit of an emerging infection. N Engl J Med 1996;334:262-3.
- Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Human
infection with Ehrlichia canis, a leucocytic rickettsia. N Engl J Med
1987;316:853-6.
- Bakken JS, Dumler JS, Chen SM, Eckman MR, Van Etta LL, Walker DH. Human
granulocytic ehrlichiosis in the upper midwest United States: a new species emerging?
JAMA 1994;272:212-8.
- Walker D, Raoult D, Brouqui P, Marrie T. Rickettsial diseases. In: Fauci AS, Braunwald
E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al., editors. Harrison's principles
of internal medicine. 14th ed. New York: The McGraw-Hill Companies; 1998. p. 1045-52.
- Walker DH, Dumler JS.
Emergence of the ehrlichioses as human health problems. Emerg Infect Dis 1996;2:18-29.
HIV-1 Subtype F in Single and Dual Infections in Puerto Rico: A
Potential Sentinel Site for Monitoring Novel Genetic HIV Variants in North America
To the Editor: Although international efforts to systematically collect,
characterize, and classify HIV isolates from around the world have increased considerably,
data on HIV-1 genetic variations in Puerto Rico are limited. This island (population 3.7
million) has one of the highest AIDS incidence rates in the United States (53.3 cases per
100,000) (1). To evaluate the potential for a multiple subtype
distribution pattern in Puerto Rico, we analyzed genetic variations between HIV-1 strains
isolated from peripheral blood mononuclear cells of 63 asymptomatic HIV-infected female
commercial sex workers from 12 communities. These participants were part of 290 female
commercial sex workers followed in a larger cross-sectional study of risk behavior (2).
HIV-1 subtypes F (n = 4) and B (n = 44) strains were identified in persons infected
with a single viral subtype with a molecular screening assay based on restriction fragment
length polymorphism (RFLP) analysis and with DNA sequencing of the viral protease
gene-prot (3). The remaining 15 specimens were classified by RFLP
as potential dual infections. Further cloning and sequencing of prot from three of these
specimens confirmed one dual infection involving subtypes F and B viruses and identified
two infections caused by genetically distinct quasispecies of subtype B variants.
In further detailed pairwise analysis of HIV-1 prot genes, a small nucleotide
divergence of 0.3% (0.0 to 1.1) within subtype F contrasted with a typical value of 6.3%
(5.1 to 7.8) for the intrasubtype distance within subtype B prot sequences (4). The 99% similarity between prot subtype F Puerto Rican sequences
suggested an epidemiologic link or a recent introduction of subtype F in Puerto Rico.
Comparative sequence analysis of the C2-V3 env is useful in establishing the time that
elapsed from infection on the basis of an annual nucleotide divergence of 0.5% to 1% in
this region (5). Such analysis has been used to study the
epidemiologic link between cases (4,6). Thus, we compared env
sequences from two of five persons infected with prot subtype F strains. This analysis
provided several observations. Env nucleotide divergence of 13.2% did not support a direct
epidemiologic link between these strains. Furthermore, the relatively high intrasubtype
diversity between env sequences suggested that evolution from a common progenitor would
have taken a minimum of approximately 13 years. Phylogenetic analysis classified these two
env sequences as subtype B, indicating that at least some of Puerto Rican prot subtype F
viruses represent HIV-1 mosaics involving closely related prot F and significantly
divergent env B sequences. Overall, discrepancy in both subtype assignment and nucleotide
diversities within prot and env regions may indicate that distinct F/B mosaics circulating
in Puerto Rico were likely the result of recombination between highly homogeneous subtype
F of relatively recent arrival and divergent resident subtype B viruses.
HIV-1 infections with subtype F strains including B/F mosaics have been reported in
Brazil (3,7). To evaluate a potential HIV-1 linkage between
Brazil and Puerto Rico, a comparative phylogenetic analysis was done on subtype F viral
prot sequences from these countries. This analysis documented that HIV-1 subtype F strains
in Puerto Rico are distinct from both Brazilian and Romanian viruses. Furthermore, our
results show that genetic analysis of prot allows tracking of subtype F viruses of
different origin. Recently, by this approach, HIV-1 prot subtype F of Puerto Rican origin
and F prot/B env mosaic were identified in HIV-1-infected persons in New York city (8). Observation of HIV-1 subtype F strains in Puerto Rico together
with the recent report describing the first cases of such infections in New York indicates
the potential for further emergence of subtype F on the North American continent. The
presence of a complex distribution pattern of subtype F infections in Puerto Rico has
serious implications for the evaluation and development of HIV diagnostics and vaccines.
Supported in part by grant G12RR-03050 (Y.Y.).
The nucleotide HIV-1 sequences obtained in this study were submitted to GenBank; their
accession numbers are AF096813-AF096833.
Idhaliz Flores,* Danuta Pieniazek, Nitza Morán,* Angel Soler,* Nayra
Rodríguez,* Margarita Alegría, Mildred Vera, Luiz M. Janini, Claudiu
I. Bandea, Artur Ramos, Mark Rayfield, and Yasuhiro Yamamura*
*Ponce School of Medicine, Ponce, Puerto Rico; Centers for Disease Control and
Prevention, Atlanta, GA; University of Puerto Rico, San Juan, Puerto Rico
References
- Centers for Disease Control and Prevention. HIV/AIDS surveillance report no. 2; 1997;9.
- Drugs, HIV infection and risk behaviors among Puerto Rican sex workers, 1994-1996.
Grant: NIAID/RCMI #G12RR03051 [Dr. Margarita Alegria]. Sociomedical Research Department,
Graduate School of Public Health, University of Puerto Rico, Medical Sciences Campus, San
Juan, Puerto Rico.
- Ramos A, Tanuri A, Schechter M, Rayfield MA, Hu DJ, Cabral MC, et al. HIV-1
dual infections are an integral part of the HIV epidemic in Brazil. Emerg Infect Dis
1999;5:65-74.
- Janini LM, Tanuri A, Schechter M, Peralta JM, Vicente AC, De la Torre N, et al.
Horizontal and vertical transmission of human immunodeficiency virus type 1 dual
infections caused by viruses of subtypes B and C. J Infect Dis 1998;177:227-31.
- Myers G, Korber B, Berzofski JA, Smith RF, and Database and Analysis Staff, editors.
Human retroviruses and AIDS 1991: a compilation and analysis of nucleic acid and amino
acid sequences. Los Alamos (NM): Los Alamos National Laboratory; 1991.
- Ou CY, Ciesielski C, Myers G, Bandea CI, Luo CC, Korber BT, et al. Molecular
epidemiology of HIV transmission in a dental practice. Science 1992;256:1167-71.
- Sabino EC, Shpaer EG, Morgado MG, Korber BT, Diaz RS, Bongertz V, et al. Identification
of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F
in two epidemiologically linked individuals from Brazil. J Virol 1994;68:6340-6.
- Weidle PJ, Ganea CE, Pieniazek D, Ramos CA, Ernst JA, McGowan JP, et al. Prevalence of
HIV-1 group M, non-B-subtypes in Bronx, New York community: a sentinel site for monitoring
of HIV genetic diversity in the United States. In: Proceedings of the 12th World AIDS
Conference; 1998 Jun; Geneva, Switzerland [abstract no. 13225].
Paratyphoid Fever in India: An Emerging Problem
To the Editor: Enteric fever is a major public health problem in India, accounting
for more than 300,000 cases per year, Salmonella typhi is the most common etiologic
agent (1), but Salmonella paratyphi A, the other causative
agent, causes more asymptomatic infections than S. typhi. According to earlier
reports from India, S. paratyphi A was implicated as a causative agent in 3%-17% of
enteric fever cases (2). However, a large community-based study in
an urban slum of Delhi during October 1995 to October 1996 found that S. paratyphi A
caused approximately 20%-25% of the cases of enteric fever in this region (3). An outbreak of enteric fever due to a single S. paratyphi A
strain in an urban residential area was reported in 1996 from New Delhi, where
contaminated water was implicated as the probable source (4,5).
This outbreak prompted a retrospective analysis of the laboratory records of the All India
Institute of Medical Sciences, New Delhi, over a 5-year period (1994-1998) to study the
change, if any, in the etiology of enteric fever in North India.
We evaluated all blood culture records from the institute's clinical bacteriology
laboratory for April to October (the months with the highest number of enteric fever
cases) each year. Records were from patients residing in New Delhi and the surrounding
areas of North India. The blood was collected by a phlebotomist in the outpatient
department or by a resident doctor in hospital wards. Blood cultures were carried out by
standard laboratory technique (6). Five ml of blood was added to 50
ml of brain heart infusion broth (Hi-Media Laboratory, India) under aseptic conditions.
Bacterial identification was accomplished by standard microbiologic protocol (6). Susceptibility to antibiotics (amoxycillin, chloramphenicol,
cotrimoxazole, gentamicin, ciprofloxacin, and ceftriaxone) was tested by the comparative
disk diffusion method (Stokes method) (7). Chi-square for trend was
calculated, and the p value was determined.
The total number of blood cultures performed for enteric fever cases (10,109 in 1994,
12,092 in 1995, 17,652 in 1996, 15,997 in 1997, and 17,012 in 1998) did not change
significantly over this period. The isolation of S. typhi changed little
(Chi-square = 2.367; p = 0.123; statistically not significant). However, the proportion of
S. paratyphi A isolates rose from 6.5% in 1994 to 44.9% in 1998 (Chi-square
= 22.20; p <0.001; statistically significant). The proportion of S. paratyphi A
isolations in enteric fever cases from 1994 to 1998 was 6.5%, 21.2%, 50.5%, 30.7%, and
44.9%, respectively. Even excluding the strains from the 1996 outbreak (4),
we found that the proportion of S. paratyphi A in enteric fever cases increased
compared with S. typhi (Chi-square = 30.528; p <0.001). With our
catchment area, case definition of enteric fever, and laboratory methods remaining the
same during this period, it appears that the etiology of enteric fever in North India is
changing significantly.
The age-wise distribution of S. typhi and S. paratyphi A showed that S.
typhi was a significant isolate from children < 5 years of age, while this
distribution was not observed for S. parathyphi A, which involved those > 5
years of age. Sex was not significantly associated (mean male to female sex ratio was
32.4:18 for S. typhi and 15.8:10.6 for S. paratyphi A).
S. typhi has become increasingly sensitive to amoxycillin, chloramphenicol, and
gentamicin, increasing from 75.1% in 1994 to 96.6% in 1998 for amoxycillin, from 71.9% in
1994 to 91.6% in 1998 for chloramphenicol, and from 96.4% to 100% for gentamicin. S.
paratyphi A strains have remained uniformly sensitive (100%) to all antibiotics
(amoxycillin, chloramphenicol, and gentamicin, as well as ciprofloxacin and ceftriaxone)
used in the treatment of enteric fever. In light of reports of multidrug resistance in S.
typhi, especially to quinolones, continued surveillance and monitoring of
antimicrobial sensitivity of S. paratyphi A strains are needed.
The increase in proportion of S. paratyphi A cases, which may be due to a high
degree of clinical suspicion (with mild fever cases investigated for enteric fever),
changing host susceptibility, or even change in the virulence of the organism, should be
further investigated.
Seema Sood, Arti Kapil, Nihar Dash, Bimal K. Das, Vikas Goel, and Pradeep Seth
All India Institute of Medical Sciences, New Delhi, India
References
- Richens J. Typhoid and paratyphoid fevers. In: Oxford textbook of medicine. Weatherall
DJ, Ledingham JGG, Warrell DA, editors. Vol 1. 3rd ed. London:: Oxford Medical
Publication; 1996. p. 560-8.
- Saxena SN, Sen R. Salmonella
paratyphi A infection in India: incidence and phage types. Trans Royal Soc Trop
Med Hyg 1966;603:409-11.
- Kumar R, Sazawal S, Sinha A, Sood S, Bhan MK. Typhoid fever: contemporary issues as
related to the disease in India. Round Table Conference Series on Water Borne Diseases.
12th ed. Ranbaxy Science Foundation, New Delhi, 1997;2:31-6.
- Kapil A, Sood S, Reddaiah VP, Das BK, Seth P. Partyphoid
fever due to Salmonella enterica serotype paratyphi A. Emerg Infect Dis
1997;3:407.
- Thong K, Nair S, Chaudhry R, Seth P, Kapil A, Kumar D, et al. Molecular
analysis of Salmonella paratyphi A from an outbreak in New Delhi, India. Emerg
Infect Dis 1998;4:507-8.
- Collee JG, Duguid JP, Fraser AG, Marmion BP. Mackie and Mc Cartney practical medical
microbiology: laboratory strategy in the diagnosis of infective syndromes. 13th ed. London
(UK): Churchill Livingstone; 1989. 601-7.
- Stokes EJ, Ridgway GL. Clinical bacteriology: anti-bacterial drugs. 5th ed. London:
Edward Arnold; 1980. p. 205-19.
Hepatitis C Virus RNA Viremia in
Central Africa
To the Editor: Epidemiologic serosurveys have demonstrated high prevalence (6%-15%)
of hepatitis C virus (HCV) infection in adults in sub-Saharan Africa (1-4). Although possible false-positive HCV serologic test results
have been reported in Africa, HCV prevalence rates suggest a high rate of chronic
infection among persons with anti-HCV antibodies (5,6). We have
focused on HCV RNA infectivity of blood from donors attending the National Blood Center in
Bangui, Central African Republic.
We prospectively tested all blood donors between February and April 1998 for serum
anti-HCV antibodies by both an HCV third-generation enzyme-linked immunosorbent assay
(ELISA) (Abbott HCV EIA 3.0 test, Abbott, Chicago, IL, USA), which was chosen as a
reference test for immunoglobulin (Ig) G antibodies to HCV, and by a simple membrane
immunoassay system (Ortho HCV Ab Quik Pack, Ortho Diagnostic Systems Inc., Tokyo, Japan) (7). Anti-HCV-positive serum samples were further subjected to
qualitative detection of HCV RNA by reverse transcription-polymerase chain reaction
(AMPLICOR-HCV, Roche Diagnostic Systems, Inc., Branchburg, NJ, USA) (8).
Of 163 serum samples (mean age ± standard deviation, 30±8 years), 155 were from male
blood donors, 83 (51%) from first-time donors, and 125 (77%) from donors in the
recipient's family. Fifteen (9.2%; 95% confidence interval [CI] 5%-15%) samples contained
IgG to HCV by ELISA. Of the ELISA-positive samples, 14 were positive by the Quik Pack
assay (sensitivity, 93.0%); of the 148 remaining ELISA-negative samples, 147 were negative
by the Quik Pack assay (specificity, 99.3%). The agreement between the results of the two
methods was 98.7%. Of the 163 samples, 10 (6.1%; CI 95%: 3%-11%) were positive for HCV
antibodies (by ELISA and rapid test) and for HCV RNA.
We confirmed a high prevalence of HCV-seropositivity among blood donors in Bangui and
the subsequent high rate of HCV RNA viremic blood donations. To offset the major risk for
transfusion-acquired HCV in Central Africa we recommend screening donated blood for
anti-HCV. When laboratory facilities to perform ELISA are not available, the Quik Pack
system, a simple reliable method for detecting anti-HCV antibodies in human serum that
requires neither complex reagent preparation nor expensive instrumentation, could prove
useful.
Nicole Cancré,* Gérard Grésenguet, François-Xavier Mbopi-Kéou,
Alain Kozemaka, Ali Si Mohamed,* Mathieu Matta,* Jean-Jacques
Fournel,§ and
Laurent Bélec*
*Université Pierre et Marie Curie, Hôpital Broussais, Paris, France; Centre
National de Transfusion Sanguine, Bangui, République Centrafricaine; London School
of Hygiene and Tropical Medicine, London, United-Kingdom; and §Hôpital de la
Pitié-Salpêtrière, Paris, France
References
- Ndumbe PM, Skalsky J. Hepatitis
C virus infection in different populations in Cameroon. Scand J Infect Dis
1993;25:689-92.
- Xu LZ, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis
C virus genotype 4 highly prevalent in Central Africa (Gabon). J Gen Virol
1994;75:2393-8.
- Fretz C, Jeannel D, Stuyver L, Herve V, Lunel F, Boudifa A, et al. HCV
Infection in a rural population of Central African Republic (CAR): evidence for three
additional subtypes of genotype 4. J Med Virol 1995;47:435-7.
- Pawlotsky JM, Bélec L, Grésenguet G, Desforges L, Bouvier M, Duval J, et al. High
prevalence of hepatitis B, C and E markers in young sexually active adults from the
Central African Republic. J Med Virol 1995;46:269-73.
- Aceti A, Taliani D. Hepatitis
C virus testing in African sera. Ann Intern Med 1992;116:427.
- Callahan JD, Constantine NT, Kataaha P, Zhang X, Hyams KC, Bansal J. Second
generation hepatitis C virus assays: performance when testing African sera. J Med
Virol 1993;41:35-8.
- Kodama T, Ichiyama S, Sato K, Nada T, Nakashima N.
Evaluation of a membrane filter assay system, Ortho HCV Ab Quik Pack, for detection of
anti-hepatitis C virus antibody. J Clin Microbiol 1998;36:1439-40.
- Young KKY, R. Resnick RM, Myers TW.
Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain
reaction assay. J Clin Microbiol 1993;31:882-6.
To the Editor: The immunization status of military contingents arriving from
different nations for peacekeeping missions may vary widely. This variation results from
lack of information, coordination, and financial support.
For larger missions, the United Nations (UN) Headquarters issues recommendations about
needed vaccines; recently, operations officers have consulted World Health Organization
experts before issuing recommendations, and their advice, which takes into account
epidemiologic data in the host country, has improved. Medical officers who develop
recommendations for smaller missions must consider the pathogenic agent; environment; host
efficacy, safety, and price of preventive measures; and legal and ethical aspects.
Data on the incidence of vaccine-preventable diseases within a military population that
had similar duties in the same location are rarely available. When data from the
respective region are not available, disease incidence or prevalence in the host country
may be substituted. These data, however, may be misleading since the military often does
not have the same lifestyle as the native population. Plague, for instance, had an
incidence rate of 8 per 100,000 in Namibia, but not a single case was reported in the
South African Armed Forces (unpub. SAMS report: Disease Profile of South West Africa,
1989). If epidemiologic documentation for a host country is not available, data from
neighboring countries may be useful.
Traveler's diarrhea is the most frequent health problem abroad (1,2).
Although the diarrhea is self-limited and lasts an average of 1 day with appropriate
treatment (4 days without), the unproductive time may be detrimental to a military
mission. Oral vaccines against the three most frequent causes of traveler's diarrhea
(enterotoxigenic Escherichia coli, Campylobacter spp., and rotavirus [1,2]) are being developed; the latter will be available soon (3). Hepatitis A, most frequent among the vaccine-preventable
diseases (4), is 10 to 100 times more frequent than typhoid
fever (4,5). Hepatitis B occurs mainly in expatriates, but
infections have also been observed in tourists who have had unprotected casual sex (6). The incidence rate of rabies is unknown, but animal bites that
may result in rabies virus transmission and thus necessitate postexposure prophylaxis are
frequent (7). Only anecdotal cases of diphtheria, tetanus, and
tuberculosis have been reported (8). Poliomyelitis, yellow
fever, Japanese encephalitis, and plague occur only in limited parts of the world (5). The situation may rapidly change as epidemics occur (e.g.,
diphtheria in eastern Europe in the early and mid-1990s) (9). If
needed, the World Health Organization can provide information on confirmed and unconfirmed
epidemics on a weekly basis.
Travel and peacekeeping mission statistics share similarities. In Namibia, the South
African Armed Forces had most often observed hepatitis (unspecified), with rare cases of
tuberculosis, typhoid, and meningitis (unpub. SAMS report: Disease Profile of South West
Africa, 1989), as did the UN mission to Namibia, where within 12 months and with 7,114
employees, seven cases of hepatitis (mostly hepatitis A, some unspecified) occurred (10). No other vaccine-preventable infections were diagnosed in this
UN mission.
Considering both risk (on the basis of incidence rates) and impact of infection, the
priority for immunization (from highest to lowest) is as follows: hepatitis A, hepatitis
B, rabies, poliomyelitis, yellow fever, typhoid fever, influenza, diphtheria, tetanus,
meningococcal disease, Japanese encephalitis, cholera, and measles. To administer all
vaccines would be extremely costly and may also result in an increased rate of adverse
side-effects. Immunizations against the more frequent, more severe infections should be
given priority.
If a mission is limited to one season, environmental factors of that respective season
should be considered. This general rule is more important for vector-borne than for
vaccine-preventable infections, except for influenza and meningococcal disease.
Persons who are already immune (because of previous immunization or immunity after
infection) need not be vaccinated. The latter cause is particularly often true of
hepatitis A; troops recruited in developing countries have an anti-hepatitis A virus
seroprevalence rate close to 100% (11). Hepatitis B immunization,
except for non- and low-responders, probably grants lifelong protection (12); the same is likely for measles vaccine.
Sometimes the host country may require proof of some specific vaccination based on the
International Health Regulations (13), currently under
fundamental revision to become a more effective tool in preventing the spread of
infections that may be a global hazard (14).
In addition to adequate epidemiologic information and coordination between the
military, international health organizations, and the host country, successful
intervention efforts require thorough knowledge of vaccine characteristics with varying
rates of efficacy and duration of protection. Cost-benefit evaluations, which would be
very desirable, are unlikely in areas of political instability.
Robert Steffen
Institute for Social and Preventive Medicine of the University, Zurich, Switzerland
1Presented in part at the NATO Research & Technology
Organization, Aerospace Medical Panel Symposium on Aeromedical Support Issues in
Contingency Operations, Rotterdam, The Netherlands, 1 October 1997.
References
- DuPont HL, Ericsson C. Prevention and treatment of travelers' diarrhea. Drug Therapy
1993;328:1821-7.
- Farthing MJG, DuPont HL, Guandalini S, Keusch GT, Steffen R. Treatment and prevention of
travellers' diarrhoea. Gastroenterology International 1992;5:162-75.
- Levine MM, Svennerholm A-M. Prioritization of vaccines to prevent enteric infections.
In: DuPont HL, Steffen R, editors. Textbook of travel medicine. 1st ed. Hamilton: B.C.
Becker Inc.; 1997. p. 370.
- Steffen R, Kane MA, Shapiro CN, Schoellhorn JK, Van Damme P. Epidemiology
and prevention of hepatitis A in travelers. JAMA 1994;272:885-9.
- World Health Organization. International travel and health. Geneva: The Organization;
1999.
- Steffen R.
Risk of hepatitis B for travellers. Vaccine 1990;8:31-2.
- Hatz CF, Bidaux JM, Eichenberger K, Mikulics U, Junghanss T. Circumstances
and management of 72 animal bites among long-term residents in the tropics. Vaccine
1994;13:811-5.
- Steffen R. Travel
medicine prevention based on epidemiological data. Trans R Soc Trop Med Hyg
1991;85:156-62.
- Hardy IRB, Dittmann S, Sutter RW. Current
situation and control strategies for resurgence of diphtheria in newly independent states
of the former Soviet Union. Lancet 1996;347:1739-44.
- Steffen R, Desaules M, Nagel J, Vuillet F, Schubarth P,
Jeanmaire C-H, et al. Epidemiological
experience in the mission of the United Nations Transition Assistance Group (UNTAG) in
Namibia. Bull World Health Organ 1992;70:129-33.
- Centers for Disease Control and Prevention. Hepatitis A immunization. MMWR Morb Mortal
Wkly Rep 1996;45(RR-15):7.
- Hall AJ. Hepatitis
B vaccination: protection for how long and against what. BMJ 1993;307:276-7.
- World Health Organization. International health regulations. 3rd annotated ed. Geneva:
The Organization; 1983.
- World Health Organization. Revision
of the international health regulations. Wkly Epidemiol Rec 1997;72:213-5.
Sexually Transmitted Diseases in Ukraine
To the Editor: With the political changes in eastern Europe in the last 10 years
have come social and economic changes (1). Ukraine not only faces
almost insurmountable problems as it tries to form a new government, it also faces many
serious health issues including sexually transmitted diseases (STDs).
Surveillance data from the Ukrainian STD Center from January 1, 1989, through December
31, 1995, were analyzed on the basis of reports received through 1997. In western Europe,
the incidence of syphilis and gonorrhea declined from 1980 to 1991 to less than 2% per
100,000 persons for syphilis and less than 20% per 100,000 persons for gonorrhea. However,
in Ukraine, since 1989, the notification rate of syphilis has skyrocketedfrom 5 per
100,000 persons in 1990 to 170 in 1995. In some regions, this rate exceeds 220 cases per
100,000 persons. Moreover, cases among children younger than 14 years of age are also
increasing. In 1995, the syphilis rate for persons older than 30 years of age was 170 per
100,000; 600 per 100,000 girls younger than 15 years of age; and 1,550 to 2,000 per
100,000 girls 15 to 16 years of age. The large number of girls with the disease is in part
due to teenage prostitution (1).
Most syphilis and gonorrhea cases are attributed to sexual transmission. Explanations
of this phenomenon include the rapid growth of the sex industry, increasing numbers of
homeless persons and refugees in Ukrainian cities, poor diagnostic facilities, punitive
legislation that reduces the likelihood of going to treatment services, and limited or
inadequate treatment (2).
The Ukrainian government is reviewing its arrangements for the control of STDs,
including HIV/AIDS, to identify clear objectives and priorities. Education and treatment
would be effective in preventing the spread of STDs in Ukraine, but these measures are
inadequately funded (3). Evaluation and risk reduction are also
great weapons in preventing the spread of STDs (4). However, the
response of the local and world communities has been inadequate in stemming a major STD
epidemic in Ukraine.
United Nation's Children's Fund (UNICEF) is developing a long-term program in Ukraine
with a focus on STDs in adolescents and youth. This comprehensive program will tackle not
only STDs but other related issues, such as HIV and teenagers' reproductive health (5).
Greater coordination of the agencies responsible for STD control in Ukraine will be
sought, together with an expansion of health promotion and prevention projects for young
persons and groups at high risk (6). An effective strategy for
the control of STDs in Ukraine will, therefore, need to find ways to modify current
programs and the way they interact to create effective control interventions.
Dmitry I. Ivanov
University of Alabama at Birmingham, Birmingham, Alabama, USA
References
- Dittmann S, Gromyko A, Mikkelsen H, Schaumburg A, Adamian R, Khodakevich L, et al.
Epidemic of sexually transmitted diseases in eastern Europe. Geneva: World Health
Organization; 1996.
- Kobyshcha Y. HIV risk-related behavior of homo and bisexual men and STD patients in
Ukraine. National AIDS Committee and Center 1994;7:290-3.
- Normand J, Vlahov D, Moses LE. Preventing HIV transmission: the role of sterile needles
and bleach. The effects of needle exchange programs. Washington: National Academy Press;
1995. p. 208-55.
- Spinhenko Y. Prevention of the spread of AIDS in the Ukrainian SSR. Lik Sprava
1988;9:1-3.
- Usenko A, Grazhdanov N, Stepanets V, Neshcheret E, Maksiutenko E. Effective
knowledge propaganda in the chief strategy for preventing HIV infection among adolescents.
Lik Sprava 1994;9:192-6.
- Tichonova L, Borisenko K, Ward H, Meheus A, Gromyko A, Renton A, et al.
Epidemics of syphilis in the Russian Federation: trends, origins, and priorities for
control. Lancet 1997;350:210-3.
Yellow Fever Vaccine
To the Editor: Monath et al. (1) outlined existing
facilities for distribution of yellow fever vaccines in the United States and pointed to
difficulties for prospective vaccinees in remote locations. Their recommendation that
primary health-care providers be allowed to dispense yellow fever vaccination merits
serious consideration. Acceptance of such a strategy in the United States would inevitably
be emulated elsewhere. Nevertheless, before such a strategy is approved, vaccine potency
should be monitored at distribution points, and a sample of vaccine recipients should be
examined for vaccine-induced immune response.
In Nigeria, systematic investigation of yellow fever vaccine distribution and
transportation to remote locations has found loss in vaccine potency. Vaccine in storage
sites and immunization centers in Lagos was fully potent, but potency in Osun and Oyo was
016 log10 to 0.22 log10 lower than the stipulated level (2). Furthermore, the titer of two vaccine lots that had been frozen
after reconstitution from their lyophilized state dropped from the initial 3.15 log10
to 3.53 log10 to zero.
If the United States were to implement an extended strategy, similar studies of vaccine
lots should be conducted to determine whether every vaccinee has received a full dose of
yellow fever vaccine. In Illinois during the early 1970s, weak links in maintenance of
refrigeration facilities and use of outdated vaccines in vials exposed to the sun for long
hours were reported for live poliovirus vaccines (3). In the
Northern Territory of Australia, examination of 144 vials of hepatitis B vaccine
formulations during transport to immunization centers showed that 47.5% had been exposed
to temperatures of -3°C or lower (4).
Assays of the potency of yellow fever vaccine, as well as quantification of
vaccine-induced neutralizing antibody, is a multistep procedure that relies on inoculation
of mice or Vero or polysaccharide cells (5). The successful
"take" of yellow fever vaccine can be determined starting the second
postvaccination day by demonstrable viremia detected by reverse-transcriptase polymerase
chain reaction and by marked increases in neopterin, beta2-microglobulin, and circulating
CD8+ cells (6). Alternatively, elevated levels of tumor
necrosis factor and interleukin-1 receptor antagonists on day two after vaccination (7) could be used to monitor the success of vaccinations by
primary-care providers in remote areas in the United States (1) and
elsewhere.
During the 1990s, isolation of yellow fever virus was reported in persons with a
nonspecific febrile illness that did not meet the case definition of yellow fever (8). Air travel by such persons to the United States, which has areas
infested by Aedes aegypti, could initiate yellow fever epidemics; because these
travelers would have a nonspecific febrile illness, they would escape the existing
surveillance network.
In conclusion, introducing yellow fever immunizations by primary health-care providers
would be ideal, only with a concurrent plan to monitor vaccine potency at immunization
centers and obtain in vitro evidence of a successful vaccine take. Such a strategy would
blunt yellow feverassociated deaths, illnesses, and symptomless viral carriage in
the community.
Subhash C. Arya
Centre for Logistical Research and Innovation New Delhi, India
References
- Monath TP, Giesberg JA, Fierros EG. Does
restricted distribution limit access and coverage of yellow fever vaccine in the United
States? Emerg Infect Dis 1998:4:698-702.
- Adu FD, Adedeji AA, Esan JS, Odusanya OG. Live
viral vaccine potency: an index for assessing the cold chain system. Public Health
1996;110:325-30.
- Rasmussen CM, Thomas CW, Mulrooney RJ, Morrissey RA.
Inadequate poliovirus immunity levels in immunised Illinois children. Am J Dis Child
1973;126:465-9.
- Miller NC, Harris MF.
Are childhood immunization programmes in Australia at risk? Investigations of the cold
chain in the Northern Territory. Bull WHO 1994;72:401-8.
- World Health Organization. Techniques for potency evaluation of yellow fever vaccine.
Technical Report Series 1998;872:67-8.
- Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J.
Development of viremia and humoral and cellular parameters of immune activation after
vaccination with yellow fever virus strain 17D: a model of human flavivirus infection.
J Med Virol 1998;56:159-67.
- Hacker UT, Jelinek T, Erhardt S, Eigier A, Hartmann G, Nothdurft HD, et al.
In vivo syntheses of tumor necrosis factor-alpha in healthy humans after live yellow fever
vaccination. J Infect Dis 1998;177:774-8.
- Sanders EJ, Maffin AA, Tukei PM, Kuria G, Ademba G, Agata NN, et al. First
recorded outbreak of yellow fever in Kenya, 1992-1993. I. Epidemiologic investigations. Am
J Trop Med Hyg 1998;59:644-9.
Yellow Fever VaccineReply to S. Arya
To the Editor: Dr. Arya correctly points out that there have been problems with
degradation of live viral vaccines, including yellow fever vaccines, that have not been
properly handled and stored at the point of use. However, in the United States and western
Europe, yellow fever vaccines are stabilized and require the same storage facilities at
the point of use as other vaccines routinely distributed by family physicians and
pediatricians. Varicella vaccine (and even measles vaccine) is less stable than yellow
fever vaccine but is distributed to all registered physicians in the United States. Since
vaccines and other perishable medicines are typically shipped by overnight courier
services using qualified methods that ensure maintenance of low temperature, there is no
barrier to use of a similar system for yellow fever vaccine.
Empirical testing for antibody, viremia, or even surrogate markers of T-cell activation
may be useful; however, it is difficult and expensive, involves unvalidated tests with
unknown sensitivity and specificity, and is unnecessary, except under very special
circumstances. A more direct measure of vaccine stability is direct potency measurement of
samples stored at the point of use, as was done in the cited study in Nigeria by Adu et
al. However, given the current controls on vaccine distribution in the United States, we
do not believe that there would be a need to validate vaccine effectiveness at point of
use in the event of a change of policy with respect to vaccinating centers. The cold-chain
infrastructure and the training of medical personnel in vaccine storage and administration
may not provide the same assurances in other countries. While our suggested changes to the
system of yellow fever distribution may improve vaccine coverage and have other desirable
benefits in the United States, they would not be appropriate for less stable systems for
vaccine supply and use.
T.P. Monath, J.A. Giesberg, and E.G. Fierros
OraVax, Cambridge, Massachusetts, USA
|